News

Sanofi Pasteur has submitted to the FDA, a supplemental application for licensure of its influenza A(H1N1) 2009 monovalent vaccine. Responding to recent recommendations by the FDA, the company’s

Labopharm’s revenue for the second quarter of fiscal 2009 increased to $6.3m from $4.9m in the second quarter of fiscal 2008. Revenue for the first half of fiscal

Watson has announced that one lot of 100mcg/hr Fentanyl Transdermal System patches sold in the US, is being voluntarily recalled from wholesalers and pharmacies. The recalled patches are

Antisoma has reported that the phase II trial of AS1402 in breast cancer is to be discontinued. This follows a meeting of the trial’s Data Monitoring Committee (DMC)

Murray, Frank & Sailer has filed a class action suit in the Southern District of Texas Houston Division, against Repros Therapeutics and some of its officers and directors.

Novavax has reported a net loss of $8.5m, or $0.10 per share, for the second quarter of 2009 compared to a net loss of $9.4m, or $0.15 per

GeoVax Labs, an Atlanta-based biopharmaceutical company developing human vaccines for diseases caused by HIV-1 and other infectious agents, has recorded a net loss of $1.34m for the three

Merck & Co.’s shareholders have approved the proposed merger with Schering-Plough. The preliminary tabulation indicates that more than 99% of the company’s outstanding shares voted in favor of

Warner Chilcott’s revenue in the quarter ended June 30, 2009 increased 7.1% to $250.8m over the prior year quarter. The company reported net income of $56m, or $0.22